Complement and Reduction of Infarct Size After Angioplasty or Lytics - CARDINAL

Description:

CARDINAL was a randomized, multi-dose study of the humanized anti-C5 complement monoclonal antibody fragment pexelizumab added to either thrombolytic therapy or percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (MI).